Moderator: Khushita Vasant

Khushita covers US antitrust enforcement and litigation for MLex in Washington, DC. She previously covered EU competition law in Brussels where she broke news on high-profile antitrust and merger investigations. She has covered the EU’s actions against Google, Apple, Facebook, and Amazon, to name a few. Now in the US, she closely tracks landmark antitrust lawsuits and investigations initiated by the Department of Justice and Federal Trade Commission against some large digital platforms. She’s often in federal courts across the US to report on high-profile civil and criminal antitrust litigation, and on Capitol Hill to cover developments on a set of critical antitrust bills pending in Congress. Khushita specializes in coverage of intellectual property, with notable scoops on US policy developments and EU investigations in the field of standard-essential patents. Her articles on SEPs have been nominated for the Concurrences Antitrust Writing Awards. Khushita previously wrote about monetary policy, and the bond and FX markets for The Wall Street Journal and Dow Jones Newswires in Mumbai.

When AI Helps Generate Inventions, Who Is the Inventor?

By Andrei Iancu and Rama Elluru This commentary from the CSIS-SCSP Task Force on IP in the AI Era was originally published in the Special Competitive Studies Project’s Substack on February 15, 2024. With roots in the U.S. constitution, patent rights provide an exclusive property right in new inventions like drugs,
Read More

Standard Essential Patents and European Economic Security

By Kirti Gupta and Chris Borges On April 27, 2023, the European Commission published a draft proposal on standard essential patents (SEPs) seeking to address the perceived lack of transparency and predictability in the licensing of SEPs. The commission proposes the creation of a competence center within the European Union Intellectual
Read More

Proposed Federal Use of March-in Rights Would Weaken American Innovation

By Sujai Shivakumar and Thomas Howell   The Biden administration is considering exercising something called “march-in rights” as a policy prescription to curb drug prices. But as with any prescription, there is a need to weigh efficacy against the side-effects. In this case, there is evidence that the vast majority of
Read More